Head and Neck Squamous Cell Carcinoma (HNSCC)
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
RegeneronTARRYTOWN, NY
1 program1
FDC fianlimab+cemiplimabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
2030
RegeneronFDC fianlimab+cemiplimab
Recursion PharmaceuticalsGTAEXS617
Boehringer IngelheimBI 765063
Clinical Trials (3)
Total enrollment: 398 patients across 3 trials
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Start: Mar 2026Est. completion: Dec 2030120 patients
Phase 2Not Yet Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Start: Jul 2023Est. completion: May 2028230 patients
Phase 1/2Recruiting
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Start: Apr 2022Est. completion: Jul 202648 patients
Phase 1Active Not Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3m ago
Office Administrator
SystImmune
3m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
17m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
17m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 398 patients
3 companies competing in this space